Back
Salesforce Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Buy
64
CRM
Salesforce
Last Price:
257.20
Seasonality Move:
9.27%
Buy
51
ALNY
Alnylam Pharmaceuticals
Last Price:
242.97
Seasonality Move:
20.36%
Buy
64
Salesforce (CRM)
is a Buy
Is Salesforce a Buy, Sell or Hold?
- The current Salesforce [CRM] share price is $252.85. The Score for CRM is 64, which is 28% above its historic median score of 50, and infers lower risk than normal.
- CRM is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Buy
51
Alnylam Pharmaceuticals (ALNY)
is a Buy
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $247.00. The Score for ALNY is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.
- ALNY is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
CRM Stock Price Chart
What is Salesforce's stock price today?
-
The Salesforce share price today is $252.85
The current trend is relatively stagnant and CRM is experiencing slight buying pressure.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $247.00
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ALNY is experiencing slight selling pressure.
CRM Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -5.4 | Sell |
| Relative Strength Index (14 RSI): | 53.59 | Buy |
| Chaikin Money Flow: | 2323920 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (228.57 - 261.65) | Buy |
| Bollinger Bands (100): | (255.27 - 303.65) | Sell |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 20.83 | Buy |
| Relative Strength Index (14 RSI): | 90.67 | Buy |
| Chaikin Money Flow: | -365678 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (135.21 - 198.95) | Buy |
| Bollinger Bands (100): | (137.63 - 173.99) | Buy |
CRM Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 240.86 | Buy |
| 20-day SMA: | 237.58 | Buy |
| 50-day SMA: | 260.92 | Sell |
| 200-day SMA: | 257.05 | Sell |
| 8-day EMA: | 243.02 | Buy |
| 20-day EMA: | 245.03 | Buy |
| 50-day EMA: | 258.03 | Sell |
| 200-day EMA: | 256.21 | Sell |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 198.72 | Buy |
| 20-day SMA: | 171.59 | Buy |
| 50-day SMA: | 157.67 | Buy |
| 200-day SMA: | 165.81 | Buy |
| 8-day EMA: | 210.85 | Buy |
| 20-day EMA: | 183.04 | Buy |
| 50-day EMA: | 165.87 | Buy |
| 200-day EMA: | 167.34 | Buy |
Salesforce Earnings Growth & CRM Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.37 per share, an increase next quarter of $0.22 per share, an increase this year of $3.27 per share, and an increase next year of $1.70 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.32 per share, a decrease next quarter of $0.12 per share, a decrease this year of $0.46 per share, and an increase next year of $1.83 per share.
Salesforce Technical Analysis
| Jun 13 | Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 13 | 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Jun 13 | Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 13 | 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||